Quantcast

Latest Emtricitabine Stories

2014-07-24 00:21:34

MELBOURNE, Australia, July 24, 2014 /PRNewswire/ -- Announced at the 20th International AIDS Conference in Melbourne, the agreement seeks to increase access to a promising new HIV medicine in 112 developing countries At the AIDS 2014 conference in Melbourne today, the Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine currently...

2014-07-21 11:19:15

The JAMA Network Journals Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The authors note that these findings do not provide a definitive conclusion regarding...

2014-04-15 04:20:50

LONDON, April 15, 2014 /PRNewswire/ -- reViral, an antiviral drug discovery and development company, focused on diseases caused by the respiratory syncytial virus (RSV), today announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. Professor Schinazi has had a long and prestigious career in the industry having founded several successful biotechnology companies including Pharmasset, where he chaired...

2014-03-24 08:27:25

Data to be presented in April at the European Association for the Study of the Liver Meeting CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These data will be presented at the 49(th) annual meeting of the European...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2013-04-29 11:36:57

A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells. In a study conducted at Texas Biomed's Southwest National Primate Research Center, researchers found that the immune modulator GS-9620, which targets a receptor on immune cells, reduced both the virus levels and the number of infected liver cells in...

Billions Saved With Generic HIV Medication
2013-01-15 18:45:18

Lee Rannals for redOrbit.com — Your Universe Online Replacing brand-name, antiretroviral drugs recommended for control of HIV infection with generic medications could save nearly $1 billion a year on health care costs in the US. This strategy of replacing the brand-name drugs with the soon-to-be-available generic drugs could also come with its risks, diminishing the efficacy of the HIV treatment. "The switch from branded to generic antiretrovirals would place us in the...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related